Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma

W R Bezwoda¹, M A Bezwoda, L Seymour

¹Department of Medicine, University of Witwatersrand Medical School, Johannesburg, South Africa.

Leukemia & Lymphoma

|July 1, 1993

Summary

The NOPE chemotherapy regimen showed a 34% complete remission rate in relapsed aggressive lymphoma patients. Favorable factors for response included early stage and non-bulky disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Investigational new drugs·2018

Same author

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Oncologists' identification of mental health distress in cancer patients: Strategies and barriers.

European journal of cancer care·2018

Same author

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Breast cancer research and treatment·2017

Area of Science:

Oncology
Hematology
Clinical Pharmacology

Background:

Relapsed aggressive lymphoma presents a significant treatment challenge.
Effective salvage chemotherapy regimens are crucial for improving patient outcomes.

Purpose of the Study:

To evaluate the efficacy and safety of the NOPE chemotherapy regimen in patients with relapsed diffuse aggressive lymphoma.
To identify factors influencing treatment response and survival.

Main Methods:

A combination chemotherapy regimen (NOPE: mitoxantrone, vincristine, prednisolone, etoposide) was administered to 43 patients.
Response was assessed by complete remission (CR) and partial response (PR).
Statistical analysis identified factors affecting response and survival.

Related Experiment Videos

Main Results:

Fourteen patients (34%) achieved CR and 6 (15%) achieved PR.
Factors associated with better response included early stage, absence of systemic symptoms, non-bulky disease, and low serum LDH (< 350 IU).
Four patients remain alive in CR (25-45+ months post-therapy).

Conclusions:

The NOPE regimen is an active and safe treatment for relapsed non-Hodgkin's lymphoma.
Achieving substantial complete remission rates is possible with this regimen.
Duration of initial response to first-line chemotherapy significantly impacts long-term outcomes.